ORCHESTRA BIOMED HOLDI

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

12 авг 2024 16:20:20 Источник Nasdaq GlobeNewswire

Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors

30 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

04 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

22 май 2024 08:43:18 Источник Nasdaq GlobeNewswire

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

13 май 2024 16:58:13 Источник Nasdaq GlobeNewswire

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

30 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

30 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

27 мар 2024 16:17:23 Источник Nasdaq GlobeNewswire

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

26 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

13 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed to Participate in Upcoming Investor Conferences

07 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

06 мар 2024 08:37:17 Источник Nasdaq GlobeNewswire

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years

26 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

08 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

13 ноя 2023 16:21:38 Источник Nasdaq GlobeNewswire

Orchestra BioMed to Present at Upcoming Investor Conferences

09 ноя 2023 16:42:43 Источник Nasdaq GlobeNewswire

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

19 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

10 авг 2023 16:34:21 Источник Nasdaq GlobeNewswire

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

08 авг 2023 08:30:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

26 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire